-
Goldman Sachs Reiterates Neutral Rating for Merck
Monday, May 7, 2012 - 10:06am | 119In a comment published earlier today, the Goldman Sachs Group, Inc. reiterated its Neutral rating for Merck & Co., Inc. (NYSE: MRK), but did not name a price target. Goldman Sachs said in its report “Roche's [F. Hoffmann-La Roche Ltd.] decision to halt all clinical trials of its CETP inhibitor...
-
UPDATE: Goldman Sachs Reiterates Buy Rating, Raises PT for Edwards Lifesciences
Wednesday, May 2, 2012 - 9:59am | 152In a company update published earlier today, the Goldman Sachs Group, Inc. reiterated its Buy rating for Edwards Lifesciences Corp. (NYSE: EW) and raised its price target from $90.00 to $97.00, related to the Centers for Medicare and Medicaid Services (CMS) releasing the final Medicare National...
-
Goldman Sachs Maintains Neutral Rating, Does Not Set PT for Barnes & Noble
Monday, April 30, 2012 - 11:41am | 211In a comment issued earlier today, Goldman Sachs Group, Inc. maintained its Neutral rating for Barnes & Noble, Inc. (NYSE: BKS) but did not set a price target, in response to the recently-formed partnership between Microsoft and Barnes & Noble and their their new subsidiary “NewCo.”...
-
UPDATE: Goldman Sachs Reiterates Buy Rating, Raises PT for Williams Companies
Friday, April 27, 2012 - 9:39am | 100In a company update released earlier today, the Goldman Sachs Group, Inc. reiterated its Buy rating for the Williams Companies, Inc. (NYSE: WMB) and raised its price target by $3.00 to $38.00. Goldman Sachs said in its report “For WMB, its chemical operation provides a natural hedge against lower...
-
UPDATE: Goldman Sachs Maintains Neutral Rating, Raises PT on Life Technologies
Wednesday, April 25, 2012 - 10:52am | 137In a company update released earlier today, Goldman Sachs Group, Inc. maintained its Neutral rating on Life Technologies Corporation (NASDAQ: LIFE) and slightly raised its price target from $46.00 to $47.00. Goldman Sachs said they maintained their rating “as we continue to see a limited path to...
-
UPDATE: Goldman Sachs Maintains Neutral Rating, Raises PT for The Home Depot
Friday, April 20, 2012 - 11:50am | 97In a company update released earlier today, the Goldman Sachs Group, Inc. maintained its Neutral rating on The Home Depot, Inc. (NYSE: HD), but raised its price target from $52 to $54. Goldman Sachs went on to say “We expect HD to revisit EBIT margin targets at its June analyst meeting. We outline...
-
UPDATE: Goldman Sachs Downgrades Lumber Liquidators to Neutral, Maintains PT
Friday, April 20, 2012 - 10:48am | 133In an action report published earlier today, the Goldman Sachs Group Inc. downgraded the rating for Lumber Liquidators Holdings, Inc. (NYSE: LL) from Buy to Neutral, but maintained its price target of $25. Goldman Sachs explained their reason for the downgrade by saying “The biggest factor is...
-
Goldman Sachs Reiterates Neutral Rating, $28 PT for Changyou.com
Monday, April 16, 2012 - 1:52pm | 165In a company update released earlier today, the Goldman Sachs Group, Inc. reiterated its Neutral rating and $28 price target for Changyou.com Limited (NASDAQ: CYOU), related to the company's recent announcement of six new games it has in development. Goldman Sachs said in the report “We do not...
-
Goldman Sachs Comments on Mattel Quarterly Reports
Monday, April 16, 2012 - 11:28am | 106In a comment report issued earlier today, the Goldman Sachs Group, Inc. offered their commentary on the quarterly results for Mattel, Inc. (NASDAQ: MAT). Goldman Sachs went on to say “US sales were down 9%. MAT indicated that sales at retail were better than retailer orders, indicating that retail...
-
UPDATE: Goldman Sachs Maintains Sell Rating, Raises PT for Forest Labs
Friday, April 13, 2012 - 9:57am | 122In a company update issued earlier today, the Goldman Sachs Group, Inc. maintained its Sell rating for Forest Laboratories, Inc. (NYSE: FRX), but raised its price target from $30 to $31. Goldman Sachs said in the report “A downward revision to the FY2013 outlook relative to last year's floor...
-
Goldman Sachs is Neutral on Computer Sciences
Wednesday, April 11, 2012 - 9:39am | 100In a comment report issued earlier today, the Goldman Sachs Group, Inc. gave a Neutral rating to Computer Sciences Corporation (NYSE: CSC), but did not name a specific price target. Goldman Sachs went on to say “We see few near-term catalysts for CSC shares and potentially more rapid deterioration...
-
Goldman Sachs Reiterates Buy, $90 PT on Monsanto
Monday, April 9, 2012 - 11:32am | 86In an action report issued earlier today, the Goldman Sachs Group, Inc. removed the Monsanto Company (NYSE: MON) from the “Conviction List,” but reiterated its Buy rating and $90 price target. Goldman Sachs said in the report “we continue to like MON's ability to drive growth regardless of...
-
Goldman Sachs Maintains Buy, $64 PT on Eastman Chemical
Monday, April 9, 2012 - 11:07am | 120In an action report issued earlier today, the Goldman Sachs Group, Inc. maintained its Buy rating and price target of $64 for Eastman Chemical Company (NYSE: EMN), along with adding Eastman to Goldman Sachs' “Conviction List.” Goldman Sachs said in the report “We believe that lower propane and...
-
UPDATE: Goldman Sachs Reiterates Buy for Magellan Midstream Partners
Wednesday, April 4, 2012 - 10:11am | 120In a company update released earlier today, Goldman Sachs Group, Inc. reiterated its Buy rating on Magellan Midstream Partners, L.P. (NYSE: MMP), along with a price target of $81. In the report, Golman Sachs said that “Strategically, Magellan has recognized the need for “shale oil”-driven...
-
Goldman Sachs, SEC Continuing Settlement Discussions
Thursday, July 15, 2010 - 9:40am | 269Shareholders have been pushing Goldman Sachs [NYSE: GS] to seek an all-in-one settlement, according to The Wall Street Journal. Goldman propositioned the SEC to continue settlement discussions. Though it isn't clear how the agency responded, the SEC likely wouldn't agree to any broad settlement...